Transforming Discovery into Opportunity

Zucara Therapeutics Announces New Board Member



VANCOUVER and TORONTO, Canada (July 10, 2017) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, is pleased to announce that Dr. Claude Piché has joined its Board of Directors.

As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the company from start up through to completion of phase III clinical studies, ultimately resulting in the sale of its glucagon nasal powder technology to Eli Lilly in October 2015. He has over 25 years of experience in developing and commercializing pharmaceuticals, vaccines, and diagnostics, including more than 15 years where he focused on diabetes therapeutics and hypoglycemia-related technologies. He has worked at large companies such as Merck, as well as start-up biopharmaceutical companies where he had roles in research, regulatory affairs, marketing, and operations.

“I’m excited to be joining a young, pre-clinical company that has so much potential. I hope to share lessons learned from successes over the past 25 years and utilize my hands-on experience in drug development, regulatory affairs, business development, marketing and fund raising,” said Dr. Claude Piché.

Michael Midmer, Chief Executive Officer of Zucara remarked, “We are honoured that Dr. Piché is joining our Board, and are very much looking forward to working with him. He brings a thoughtful and wise voice and in-depth drug development experiences that will prove invaluable for Zucara as we continue to advance our leading product toward the clinic, and ultimately improve the lives of diabetes patients worldwide.”

– 30 –

About Zucara Therapeutics Inc.
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes. The Company’s first-in-class therapeutic is aimed at inhibiting a hormone in the pancreas called somatostatin, which does not function properly in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life. www.zucara.ca

For additional information, please contact:
Julia White
Senior Manager, Communications
Email: jwhite@cdrd.ca
Direct: 604-827-1226

Sign up to our newsletter

Receive CDRD's e-newsletter, The CDRD Pipeline and other e-communications for regular updates on all our news and activities.



© Copyright 2017 CDRD. All rights reserved.

>